China CDMO (Contract Development & Manufacturing Organization) Market 2018-2021: The R&D Cost of New Drugs Continues to Rise While the Success Rate Decreases YoY
DUBLIN, Sept. 10, 2018 /PRNewswire/ --
The "China CDMO (Contract Development & Manufacturing Organization) Industry Research Report, 2018-2021" report has been added to ResearchAndMarkets.com's offering.
In 2017, China invested approximately US $13.2 billion in medical R&D, accounting for 8.9 percent of the total global medical R&D investment in the same period.
China's pharmaceutical R&D industry started late, with insufficient technical capacity and fewer investment at the initial stage of development. However, it has achieved rapid development in recent years and has great room for improvement. With the improvement of Chinese drug firms' R&D strength and the strengthening of government control of generic drugs, such as development of the generic consistency evaluation, the clinical trial data of audits and inspections, etc., the Chinese pharmaceutical R&D spending will continue to increase. China's pharmaceutical R&D spending is expected to reach US $29.2 billion in 2021, accounting for the total amount of the global pharmaceutical R&D spending will rise to 18.3%.
The global market for drug development services reached about US $71.7 billion in 2017.At a time when the cost of developing new drugs is high and generic competition is fierce around the world, pharmaceutical companies are increasingly inclined to outsource drug development to speed up the development of new drugs. The global market for drug development services is expected to grow to US $102.8 billion by 2021.
Compared with the global pharmaceutical development service market, the volume of China's pharmaceutical development service market is small, but the growth is fast. In 2017, China's drug development services market size reached approximately US $9.2 billion, and is expected to increase by 2021 to $27.8 billion.
CDMO market is developing rapidly in recent years, it is a highly fragmented industry, full of market competition. The world's leading CDMO company mainly include catalent, patheon, Lonza, BI, Jubilant, top CDMO enterprises currently accounts for the overall market share of about 18%.
In recent years, along with the great progress of China and India in talent cultivation, pharmaceutical technology research, especially in China, which has complete infrastructure, adequate raw material supply and significant operating cost advantage, these areas gradually become the CDMO emerging markets. Currently the CDMO business is transforming from developed markets to emerging markets, the CDMO market share of Europe and the United State has decreased from 75% in 2010 to 67% at present. Countries such as China and India has improved their market share from 10% to 15% at present, with China's market share accounted for about 8%.
Similar to the international market competition, China's CDMO overall market concentration is low at present, part of the CDMO players with comprehensive competitiveness such as Asymchem, STA Pharmaceutical, WuXi Biologics and Porton Fine Chemicals etc., has higher market share., but there is still no absolute leading enterprises.
Key Topics Covered:
1. Overview of Contract Development & Manufacturing Organization
1.1 Definition
1.2 Mainstream Technologies
1.2.1 Asymmetric synthesis
1.2.2 Cryogenic reaction
1.2.3 Enzymic catalytic reaction
1.2.4 High temperature and high pressure reaction
1.2.5 Crystallization technologies
1.2.6 High activity laboratory
1.3 Industry Chain
2. Policy
2.1 Snapshot of Policies
2.2 Chinese Pharmaceutical Marketing Authorisation Holder System (MAH)
3. Background of CDMO Industry
3.1 Development of Global Pharmaceuticals Industry
The global pharmaceutical industry has huge market space,with stable future growth
Europe and the United States remain the world's largest pharmaceutical market
China's future global market share will gradually increase
Drivers of Global Pharmaceuticals Industry
3.2 Why CDMO?-Reasons for the rise
The R&D cost of new drugs continues to rise while the success rate decreases year by year
Biotech companies are on the rise
Strong returns on patented drugs and pressure on patent expiry have prompted drug companies to step up R&D of new drugs
Chemical drugs remains dominate, the number of micromolecule new drugs is on the rise
3.3 Trends of global pharmaceutical market
The importance of emerging markets are increasing
The share of patented innovative drugs will continue to increase
Innovative biotechnology r&d companies continue to develop
Micromolecule chemical drugs will remain a key area of R&D for some time to come
3.4 Trends of China pharmaceutical market
The popularity of generic drugs has declined and new drugs R&D are on the rise
The pharmaceutical industry has become more innovative and small biotech companies have sprung up
4 CDMO Market
4.1 Entire Pharmaceutical Outsourcing Market
4.2 CRO Market
4.3 CDMO market
4.4 Market Landscape
4.5 Review of CDMO M&A
5 CDMO Players in China
5.1 Asymchem Laboratories (Tianjin) Co., Ltd.
5.2 WuXi Biologics (Cayman) Inc.
5.3 STA Pharmaceutical Co. Ltd.
5.4 Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
5.5 3SBio Inc.
5.6 Porton Fine Chemicals Ltd.
5.7 Lianhe Chemical Technology Co., Ltd.
5.8 Laviana Pharma Co., Ltd.
5.9 Pharmaron Beijing Co., Ltd.
5.10 PharmaResources (Shanghai) Co., Ltd.
5.11 Shanghai ChemPartner Co., Ltd.
6 Industry Development Trends
6.1 Integrated Industry Chain
Porton Fine Chemicals Ltd.-Expanding CDMO business to upstream CRO business
STA Pharmaceutical Co. Ltd. - Expanding CDMO business to downstream pharmaceutics
6.2 Bio-pharmaceutical CDMO-Main battlefield in the future
For more information about this reportvisit
https://www.researchandmarkets.com/research/f42mnz/china_cdmo?w=5
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content to download multimedia:http://www.prnewswire.com/news-releases/china-cdmo-contract-development--manufacturing-organization-market-2018-2021-the-rd-cost-of-new-drugs-continues-to-rise-while-the-success-rate-decreases-yoy-300709490.html
SOURCE Research and Markets
